Idiopathic pulmonary arterial hypertension is a rare and life-shortening condition often
diagnosed at an advanced stage. Despite increased awareness, the delay to diagnosis …

Idiopathic pulmonary arterial hypertension (iPAH) is a rare progressive, life-shortening
disease, usually diagnosed at an advanced stage. We hypothesize that patients with iPAH …

Many patients with pulmonary arterial hypertension (PAH) experience substantial delays in
diagnosis, which is associated with worse outcomes and higher costs. Tools for diagnosing …

Background The diagnosis of pulmonary arterial hypertension (PAH) is challenging, and
there is significant overlap with the more heterogenous diagnosis of pulmonary …

Background Real‐world healthcare data are an important resource for epidemiologic
research. However, accurate identification of patient cohorts—a crucial first step …

Pulmonary arterial hypertension (PAH) is rare and, if untreated, has a median survival of 2–3
years. Pulmonary arterial hypertension may be idiopathic (IPAH) but is frequently associated …

Background Study of pulmonary arterial hypertension (PAH) in claims-based (CB) cohorts
may facilitate understanding of disease epidemiology, however previous CB algorithms to …

BACKGROUND Screening and early diagnosis of pulmonary hypertension (PH) are critical
for managing progression and preventing associated mortality; however, there are no tools …

Retrospective administrative claims database studies provide real-world evidence about
treatment patterns, healthcare resource use, and costs for patients and are increasingly …

Administrative claims studies do not adequately distinguish pulmonary arterial hypertension
(PAH) from other forms of pulmonary hypertension (PH). Our aim is to develop and validate …